In this webinar, gastroenterologist Parambir S. Dulai, MD, discusses the clinical profile of obefazimod, an investigational once-daily oral small molecule being studied for the treatment of moderately to severely active ulcerative colitis and how its novel mechanism of action enhances the expression of a single microRNA, miR-124, a natural regulator of the immune response.
Sponsored by Abivax.